While the US government has funded investigations into therapeutic applications of Morpholino oligos for viruses such as Ebola and Marburg, it appears that the US government is becoming interested in Morpholinos for broader antiviral applications. Congratulations to the team at AVI BioPharma Inc. for securing funding from the Defense Threat Reduction Agency for H1N1 influenza studies! They have shown that PMO (phosphorodiamidate Morpholino oligomer) are, in the words of the DTRA document, “…a platform that can be rapidly modified to address new pathogenic threats immediately upon identification of a new threat.”

https://www.fbo.gov/download/cbb/cbb7d4265ceced4f22276e4e4d832ef9/HDTRA1-09-C-0046_J&A_.pdf